Marlies Blom

Summary

Affiliation: Radboud University Nijmegen Medical Centre
Country: The Netherlands

Publications

  1. ncbi Frequency and effectiveness of dose increase of adalimumab, etanercept, and infliximab in daily clinical practice
    M Blom
    Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Arthritis Care Res (Hoboken) 62:1335-41. 2010
  2. ncbi Management of established rheumatoid arthritis with an emphasis on pharmacotherapy
    M Blom
    Department of Rheumatology, Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HB Nijmegen, The Netherlands
    Best Pract Res Clin Rheumatol 21:43-57. 2007
  3. ncbi The reason for discontinuation of the first tumor necrosis factor (TNF) blocking agent does not influence the effect of a second TNF blocking agent in patients with rheumatoid arthritis
    Marlies Blom
    Department of Rheumatology, Radboud University Nijmegen Medical Centre, PO Box 9101, H 470, 6500 HB Nijmegen, The Netherlands
    J Rheumatol 36:2171-7. 2009
  4. ncbi Effectiveness of a third tumor necrosis factor-α-blocking agent compared with rituximab after failure of 2 TNF-blocking agents in rheumatoid arthritis
    Marlies Blom
    Department of Rheumatology, Radboud University Nijmegen Medical Centre, HB Nijmegen, The Netherlands
    J Rheumatol 38:2355-61. 2011
  5. ncbi Surgical treatment for the vulvar vestibulitis syndrome
    Maaike A F Traas
    Department of Obstetrics and Gynecology, Rijnstate Hospital, Arnhem, The Netherlands
    Obstet Gynecol 107:256-62. 2006
  6. ncbi Rituximab treatment in patients with refractory inflammatory myopathies
    Elien A M Mahler
    Department of Rheumatology, Radboud University Nijmegen Medical Centre, HB Nijmegen, The Netherlands
    Rheumatology (Oxford) 50:2206-13. 2011

Detail Information

Publications6

  1. ncbi Frequency and effectiveness of dose increase of adalimumab, etanercept, and infliximab in daily clinical practice
    M Blom
    Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Arthritis Care Res (Hoboken) 62:1335-41. 2010
    ..To describe the frequency and effectiveness of dose increase of adalimumab, etanercept, and infliximab in the treatment of rheumatoid arthritis (RA) in daily clinical practice...
  2. ncbi Management of established rheumatoid arthritis with an emphasis on pharmacotherapy
    M Blom
    Department of Rheumatology, Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HB Nijmegen, The Netherlands
    Best Pract Res Clin Rheumatol 21:43-57. 2007
    ....
  3. ncbi The reason for discontinuation of the first tumor necrosis factor (TNF) blocking agent does not influence the effect of a second TNF blocking agent in patients with rheumatoid arthritis
    Marlies Blom
    Department of Rheumatology, Radboud University Nijmegen Medical Centre, PO Box 9101, H 470, 6500 HB Nijmegen, The Netherlands
    J Rheumatol 36:2171-7. 2009
    ..To investigate whether the reason for discontinuation of the first tumor necrosis factor (TNF) blocking agent influences the effect of a second TNF blocking agent...
  4. ncbi Effectiveness of a third tumor necrosis factor-α-blocking agent compared with rituximab after failure of 2 TNF-blocking agents in rheumatoid arthritis
    Marlies Blom
    Department of Rheumatology, Radboud University Nijmegen Medical Centre, HB Nijmegen, The Netherlands
    J Rheumatol 38:2355-61. 2011
    ..To compare the effectiveness of a third tumor necrosis factor-α (TNF-α)-blocking agent with rituximab after failure of 2 TNF-blocking agents in patients with rheumatoid arthritis (RA) in daily clinical practice...
  5. ncbi Surgical treatment for the vulvar vestibulitis syndrome
    Maaike A F Traas
    Department of Obstetrics and Gynecology, Rijnstate Hospital, Arnhem, The Netherlands
    Obstet Gynecol 107:256-62. 2006
    ..To study the outcome and complications of surgical treatment for vulvar vestibulitis syndrome and to identify patient characteristics that may have influenced the outcome...
  6. ncbi Rituximab treatment in patients with refractory inflammatory myopathies
    Elien A M Mahler
    Department of Rheumatology, Radboud University Nijmegen Medical Centre, HB Nijmegen, The Netherlands
    Rheumatology (Oxford) 50:2206-13. 2011
    ..1 months of follow-up...